{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:21:58Z","timestamp":1791591718136,"version":"4.3.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Amyloid positron emission tomography (PET) with [<jats:sup>18<\/jats:sup>F]florbetaben (FBB) is an established tool for detecting A\u03b2 deposition in the brain in vivo based on visual assessment of PET scans. Quantitative measures are commonly used in the research context and allow continuous measurement of amyloid burden. The aim of this study was to demonstrate the robustness of FBB PET quantification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective analysis of FBB PET images from 589 subjects. PET scans were quantified with 15 analytical methods using nine software packages (MIMneuro, Hermes BRASS, Neurocloud, Neurology Toolkit, statistical parametric mapping (SPM8), PMOD Neuro, CapAIBL, non-negative matrix factorization (NMF), Amyloid<jats:sup>IQ<\/jats:sup>) that used several metrics to estimate A\u03b2 load (SUVR, centiloid, amyloid load, and amyloid index). Six analytical methods reported centiloid (MIMneuro, standard centiloid, Neurology Toolkit, SPM8 (PET only), CapAIBL, NMF). All results were quality controlled.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean sensitivity, specificity, and accuracy were 96.1\u2009\u00b1\u20091.6%, 96.9\u2009\u00b1\u20091.0%, and 96.4\u2009\u00b1\u20091.1%, respectively, for all quantitative methods tested when compared to histopathology, where available. The mean percentage of agreement between binary quantitative assessment across all 15 methods and visual majority assessment was 92.4\u2009\u00b1\u20091.5%. Assessments of reliability, correlation analyses, and comparisons across software packages showed excellent performance and consistent results between analytical methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study demonstrated that quantitative methods using both CE marked software and other widely available processing tools provided comparable results to visual assessments of FBB PET scans. Software quantification methods, such as centiloid analysis, can complement visual assessment of FBB PET images and could be used in the future for identification of early amyloid deposition, monitoring disease progression and treatment effectiveness.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00259-023-06279-0","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T04:01:47Z","timestamp":1686369707000},"page":"3276-3289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9997-7409","authenticated-orcid":false,"given":"Aleksandar","family":"Jovalekic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Ro\u00e9-Vellv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Koglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Lagos","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Diemling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"G\u00f3mez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Dor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierrick","family":"Bourgeat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Whittington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Bullich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,10]]},"reference":[{"issue":"2","key":"6279_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312\u201339.","journal-title":"Cell"},{"issue":"1","key":"6279_CR2","first-page":"68","volume":"8","author":"M Mil\u00e0-Alom\u00e0","year":"2021","unstructured":"Mil\u00e0-Alom\u00e0 M, et al. Comparative analysis of different definitions of amyloid-\u03b2 positivity to detect early downstream pathophysiological alterations in preclinical Alzheimer. J Prev Alzheimer\u2019s Dis. 2021;8(1):68\u201377.","journal-title":"J Prev Alzheimer's Dis"},{"issue":"1","key":"6279_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WAD.0000000000000144","volume":"30","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, et al. Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial. Alzheimer Dis Assoc Disord. 2016;30(1):1\u20137.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"6279_CR4","first-page":"218","volume":"8","author":"C Roberts","year":"2021","unstructured":"Roberts C, et al. Amyloid and APOE status of screened subjects in the elenbecestat MissionAD phase 3 program. J Prev Alzheimer\u2019s Dis. 2021;8(2):218\u201323.","journal-title":"J Prev Alzheimer's Dis"},{"issue":"10","key":"6279_CR5","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49(10):3508\u201328.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6279_CR6","unstructured":"Life Molecular Imaging, Neuraceq USPI. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/204677Orig1s021lbl.pdf. Accessed\u00a025 Jan 2023."},{"key":"6279_CR7","unstructured":"Life Radiopharma Berlin, Neuraceq SmPC. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/neuraceq-epar-product-information_en.pdf. Accessed 25 Jan 2023."},{"issue":"8","key":"6279_CR8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964\u201374.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"6279_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.2967\/jnumed.115.161927","volume":"57","author":"J Seibyl","year":"2016","unstructured":"Seibyl J, et al. Impact of training method on the robustness of the visual assessment of 18F-florbetaben PET scans: results from a phase-3 study. J Nucl Med. 2016;57(6):900\u20136.","journal-title":"J Nucl Med"},{"key":"6279_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.nicl.2017.04.025","volume":"15","author":"S Bullich","year":"2017","unstructured":"Bullich S, et al. Optimized classification of (18)F-florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. Neuroimage Clin. 2017;15:325\u201332.","journal-title":"Neuroimage Clin"},{"issue":"4","key":"6279_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/WCO.0000000000000109","volume":"27","author":"D Perani","year":"2014","unstructured":"Perani D. FDG-PET and amyloid-PET imaging: the diverging paths. Curr Opin Neurol. 2014;27(4):405\u201313.","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"6279_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2967\/jnumed.118.207811","volume":"60","author":"J Lilja","year":"2019","unstructured":"Lilja J, et al. Spatial normalization of (18)F-flutemetamol PET images using an adaptive principal-component template. J Nucl Med. 2019;60(2):285\u201391.","journal-title":"J Nucl Med"},{"issue":"5","key":"6279_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00259-016-3601-4","volume":"44","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo MJ, et al. Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. Eur J Nucl Med Mol Imaging. 2017;44(5):825\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6279_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13195-021-00807-6","volume":"13","author":"S Bullich","year":"2021","unstructured":"Bullich S, et al. Early detection of amyloid load using (18)F-florbetaben PET. Alzheimers Res Ther. 2021;13(1):67.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"6279_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2967\/jnumed.119.235879","volume":"61","author":"E Fantoni","year":"2020","unstructured":"Fantoni E, et al. The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging. J Nucl Med. 2020;61(2):166\u201371.","journal-title":"J Nucl Med"},{"issue":"12","key":"6279_CR16","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.2967\/jnumed.115.156414","volume":"56","author":"C Hosokawa","year":"2015","unstructured":"Hosokawa C, et al. Performance of 11C-Pittsburgh compound B PET binding potential images in the detection of amyloid deposits on equivocal static images. J Nucl Med. 2015;56(12):1910\u20135.","journal-title":"J Nucl Med"},{"issue":"2","key":"6279_CR17","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.neuroimage.2011.07.098","volume":"59","author":"EC Mormino","year":"2012","unstructured":"Mormino EC, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 2012;59(2):1152\u201360.","journal-title":"Neuroimage"},{"issue":"5","key":"6279_CR18","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s00259-017-3644-1","volume":"44","author":"H Barthel","year":"2017","unstructured":"Barthel H, Seibyl J, Sabri O. Yes we can analyse amyloid images - now what? Eur J Nucl Med Mol Imaging. 2017;44(5):822\u20134.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6279_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","volume":"11","author":"G Klein","year":"2019","unstructured":"Klein G, et al. Gantenerumab reduces amyloid-beta plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019;11(1):101.","journal-title":"Alzheimers Res Ther"},{"issue":"18","key":"6279_CR20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"issue":"10","key":"6279_CR21","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","volume":"79","author":"S Shcherbinin","year":"2022","unstructured":"Shcherbinin S, et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(10):1015\u201324.","journal-title":"JAMA Neurol"},{"issue":"1","key":"6279_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 2021;13(1):80.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"6279_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2022","unstructured":"van Dyck CH, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2022;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"6279_CR24","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"key":"6279_CR25","unstructured":"FDA. FDA grants accelerated approval for Alzheimer\u2019s disease treatment. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-disease-treatment. Accessed\u00a06 Jan 2023."},{"issue":"20","key":"6279_CR26","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe MJ, et al. In vivo staging of regional amyloid deposition. Neurology. 2017;89(20):2031\u20138.","journal-title":"Neurology"},{"issue":"11","key":"6279_CR27","doi-asserted-by":"publisher","first-page":"e1538","DOI":"10.1212\/WNL.0000000000010256","volume":"95","author":"LE Collij","year":"2020","unstructured":"Collij LE, et al. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology. 2020;95(11):e1538\u201353.","journal-title":"Neurology"},{"issue":"4","key":"6279_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/jnnp-2014-308094","volume":"86","author":"KT Ong","year":"2015","unstructured":"Ong KT, et al. Abeta imaging with 18F-florbetaben in prodromal Alzheimer\u2019s disease: a prospective outcome study. J Neurol Neurosurg Psychiatry. 2015;86(4):431\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"6279_CR29","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","volume":"44","author":"CC Rowe","year":"2017","unstructured":"Rowe CC, et al. (18)F-Florbetaben PET beta-amyloid binding expressed in CENTILOIDS. Eur J Nucl Med Mol Imaging. 2017;44(12):2053\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6279_CR30","unstructured":"Piper J, Nelson A, Javorek A. Evaluation of a quantitative method for florbetaben (FBB) PET using SUVR. in EANM. 2014."},{"key":"6279_CR31","doi-asserted-by":"crossref","unstructured":"Klunk WE, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1\u201315 e1\u20134.","DOI":"10.1016\/j.jalz.2014.07.003"},{"issue":"21","key":"6279_CR32","doi-asserted-by":"publisher","first-page":"e2834","DOI":"10.1212\/WNL.0000000000011031","volume":"95","author":"A Leuzy","year":"2020","unstructured":"Leuzy A, et al. Derivation and utility of an Abeta-PET pathology accumulation index to estimate Abeta load. Neurology. 2020;95(21):e2834\u201344.","journal-title":"Neurology"},{"issue":"1","key":"6279_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084777","volume":"9","author":"L Zhou","year":"2014","unstructured":"Zhou L, et al. MR-less surface-based amyloid assessment based on 11C PiB PET. PLoS ONE. 2014;9(1): e84777.","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"6279_CR34","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1016\/j.neurobiolaging.2014.04.033","volume":"36","author":"P Bourgeat","year":"2015","unstructured":"Bourgeat P, et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging. 2015;36(Suppl 1):S159\u201366.","journal-title":"Neurobiol Aging"},{"key":"6279_CR35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.neuroimage.2018.08.044","volume":"183","author":"P Bourgeat","year":"2018","unstructured":"Bourgeat P, et al. Implementing the centiloid transformation for (11)C-PiB and beta-amyloid (18)F-PET tracers using CapAIBL. Neuroimage. 2018;183:387\u201393.","journal-title":"Neuroimage"},{"key":"6279_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117593","volume":"226","author":"P Bourgeat","year":"2021","unstructured":"Bourgeat P, et al. Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies. Neuroimage. 2021;226: 117593.","journal-title":"Neuroimage"},{"issue":"5","key":"6279_CR37","doi-asserted-by":"publisher","first-page":"822","DOI":"10.2967\/jnumed.117.194720","volume":"59","author":"A Whittington","year":"2018","unstructured":"Whittington A, et al. Spatiotemporal distribution of beta-amyloid in Alzheimer disease is the result of heterogeneous regional carrying capacities. J Nucl Med. 2018;59(5):822\u20137.","journal-title":"J Nucl Med"},{"key":"6279_CR38","doi-asserted-by":"crossref","unstructured":"Whittington A, Gunn RN; I. Alzheimer\u2019s Disease Neuroimaging. Amyloid load: a more sensitive biomarker for amyloid imaging. J Nucl Med. 2019;60(4):536\u2013540.","DOI":"10.2967\/jnumed.118.210518"},{"issue":"4","key":"6279_CR39","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s00259-020-05044-x","volume":"48","author":"JY Kim","year":"2021","unstructured":"Kim JY, et al. Visual interpretation of [(18)F]florbetaben PET supported by deep learning-based estimation of amyloid burden. Eur J Nucl Med Mol Imaging. 2021;48(4):1116\u201323.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"6279_CR40","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s00259-021-05311-5","volume":"48","author":"M Bucci","year":"2021","unstructured":"Bucci M, et al. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [(18)F]flutemetamol amyloid PET images. Eur J Nucl Med Mol Imaging. 2021;48(7):2183\u201399.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6279_CR41","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.nicl.2016.05.004","volume":"12","author":"L Cattell","year":"2016","unstructured":"Cattell L, et al. Classification of amyloid status using machine learning with histograms of oriented 3D gradients. Neuroimage Clin. 2016;12:990\u20131003.","journal-title":"Neuroimage Clin"},{"issue":"1","key":"6279_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.15616\/BSL.2019.25.1.99","volume":"25","author":"K Cho","year":"2019","unstructured":"Cho K, et al. Classification of 18F-florbetaben amyloid brain PET image using PCA-SVM. Biomed Sci Lett. 2019;25(1):99\u2013106.","journal-title":"Biomed Sci Lett"},{"issue":"1","key":"6279_CR43","doi-asserted-by":"publisher","first-page":"19576","DOI":"10.1038\/s41598-020-76102-5","volume":"10","author":"SH Cho","year":"2020","unstructured":"Cho SH, et al. Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments. Sci Rep. 2020;10(1):19576.","journal-title":"Sci Rep"},{"issue":"1","key":"6279_CR44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2174\/1874471013666200729155717","volume":"14","author":"G Giovacchini","year":"2021","unstructured":"Giovacchini G, et al. Impact of tracer retention levels on visual analysis of cerebral [(18)F]- florbetaben PET images. Curr Radiopharm. 2021;14(1):70\u20137.","journal-title":"Curr Radiopharm"},{"issue":"2","key":"6279_CR45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.23838\/pfm.2021.00023","volume":"5","author":"H-R Kim","year":"2021","unstructured":"Kim H-R, et al. Finding the optimal cutoff value for amyloid \u03b2 positivity using the iterative outlier method and concordance rate. Precis Futur Med. 2021;5(2):83\u20139.","journal-title":"Precis Futur Med"},{"issue":"8","key":"6279_CR46","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00259-019-04663-3","volume":"47","author":"JP Kim","year":"2020","unstructured":"Kim JP, et al. Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes. Eur J Nucl Med Mol Imaging. 2020;47(8):1971\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6279_CR47","unstructured":"Whittington A, et al. AmyloidIQ \u2013 an automated algorithm for classifying amyloid-\u03b2 PET scans. In: Human Amyloid Imaging. 2019. https:\/\/hai.worldeventsforum.com\/wp-content\/uploads\/2019\/01\/HAI-Book-Print-Jan-8.pdf. Accessed 25 Jan 2023."},{"issue":"S6","key":"6279_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/alz.066217","volume":"18","author":"E Zeltzer","year":"2022","unstructured":"Zeltzer E, et al. Quantitative analysis of 6,150 real-world amyloid positron emission tomography (PET) scans from the imaging dementia\u2013evidence for amyloid scanning (IDEAS) study. Alzheimer\u2019s Dement. 2022;18(S6): e066217.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"8","key":"6279_CR49","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669\u201378.","journal-title":"Lancet Neurol"},{"issue":"3","key":"6279_CR50","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72(3):287\u201394.","journal-title":"JAMA Neurol"},{"key":"6279_CR51","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez G, et al. 18F PET with florbetaben for the early diagnosis of Alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;11(11):Cd012883.","DOI":"10.1002\/14651858.CD012883"},{"key":"6279_CR52","doi-asserted-by":"publisher","unstructured":"Collij LE, et al. Quantification of [(18) F]florbetaben amyloid-PET imaging in a mixed memory clinic population: the ABIDE project. Alzheimers Dement. 2022.\u00a0https:\/\/doi.org\/10.1002\/alz.12886.","DOI":"10.1002\/alz.12886"},{"issue":"1","key":"6279_CR53","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00259-020-04942-4","volume":"48","author":"BJ Hanseeuw","year":"2021","unstructured":"Hanseeuw BJ, et al. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. Eur J Nucl Med Mol Imaging. 2021;48(1):302\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"6279_CR54","doi-asserted-by":"crossref","first-page":"e662","DOI":"10.1212\/WNL.0000000000011222","volume":"96","author":"LM van der Kall","year":"2021","unstructured":"van der Kall LM, et al. Association of \u03b2-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals. Neurology. 2021;96(5):e662\u201370.","journal-title":"Neurology"},{"issue":"11","key":"6279_CR55","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28(11):2381\u20137.","journal-title":"Nat Med"},{"issue":"9","key":"6279_CR56","doi-asserted-by":"publisher","first-page":"e1347","DOI":"10.1212\/WNL.0000000000011524","volume":"96","author":"WJ Jagust","year":"2021","unstructured":"Jagust WJ, Landau SM. Temporal dynamics of \u03b2-amyloid accumulation in aging and Alzheimer disease. Neurology. 2021;96(9):e1347\u201357.","journal-title":"Neurology"},{"key":"6279_CR57","doi-asserted-by":"crossref","unstructured":"Matsuda H, et al. Quantitative evaluation of 18F-flutemetamol PET in patients with cognitive impairment and suspected Alzheimer\u2019s disease: a multicenter study. Front Neurol. 2021;11:578753.","DOI":"10.3389\/fneur.2020.578753"},{"issue":"1","key":"6279_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12216","volume":"13","author":"LE Collij","year":"2021","unstructured":"Collij LE, et al. Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. Alzheimers Dement (Amst). 2021;13(1): e12216.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"S5","key":"6279_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/alz.044786","volume":"16","author":"S Bullich","year":"2020","unstructured":"Bullich S, et al. Converging evidence for a \u201cgray-zone\u201d of amyloid burden and its relevance. Alzheimers Dement. 2020;16(S5): e044786.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"6279_CR60","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvado","year":"2019","unstructured":"Salvado G, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11(1):27.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"6279_CR61","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jalz.2019.02.005","volume":"15","author":"V Dore","year":"2019","unstructured":"Dore V, et al. Comparison of (18)F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL((R)) approaches: validation against histopathology. Alzheimers Dement. 2019;15(6):807\u201316.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"6279_CR62","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, et al. Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15(2):205\u201316.","journal-title":"Alzheimers Dement"},{"key":"6279_CR63","doi-asserted-by":"crossref","unstructured":"Su Y, et al. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage: Clinical 2018;19:406\u2013416.","DOI":"10.1016\/j.nicl.2018.04.022"},{"issue":"S6","key":"6279_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/alz.067896","volume":"18","author":"M Shekari","year":"2022","unstructured":"Shekari M, et al. Evaluating the sensitivity of Centiloid quantification to pipeline design and image resolution. Alzheimers Dement. 2022;18(S6): e067896.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"6279_CR65","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamaneurol.2019.2214","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, et al. Staging beta-amyloid pathology with amyloid positron emission tomography. JAMA Neurol. 2019;76(11):1319\u201329.","journal-title":"JAMA Neurol"},{"issue":"11","key":"6279_CR66","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jalz.2018.05.013","volume":"14","author":"T Guo","year":"2018","unstructured":"Guo T, et al. Rate of beta-amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials. Alzheimers Dement. 2018;14(11):1387\u201396.","journal-title":"Alzheimers Dement"},{"key":"6279_CR67","doi-asserted-by":"crossref","unstructured":"Insel PS, et al. Neuroanatomical spread of amyloid beta and tau in Alzheimer's disease: implications for primary prevention. Brain Commun. 2020;2(1):fcaa007.","DOI":"10.1093\/braincomms\/fcaa007"},{"issue":"5","key":"6279_CR68","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/alz.12069","volume":"16","author":"I Lopes Alves","year":"2020","unstructured":"Lopes Alves I, et al. Quantitative amyloid PET in Alzheimer\u2019s disease: the AMYPAD prognostic and natural history study. Alzheimers Dement. 2020;16(5):750\u20138.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"6279_CR69","volume":"12","author":"TA Pascoal","year":"2020","unstructured":"Pascoal TA, et al. Topographical distribution of Abeta predicts progression to dementia in Abeta positive mild cognitive impairment. Alzheimers Dement (Amst). 2020;12(1): e12037.","journal-title":"Alzheimers Dement (Amst)"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06279-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06279-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06279-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T22:29:38Z","timestamp":1702592978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06279-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,10]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6279"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06279-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,10]]},"assertion":[{"value":"27 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aleksandar Jovalekic, N\u00faria Ro\u00e9-Vellv\u00e9, Norman Koglin, Mariana Lagos Quintana, Andrew W.\u00a0Stephens and Santiago Bullich are employees of Life Molecular Imaging GmbH (formerly Piramal Imaging GmbH).Aaron Nelson is an employee of MIM Software\u00a0Inc.Markus Diemling and Johan Lilja are employees of Hermes Medical Solutions.Juan Pablo G\u00f3mez-Gonz\u00e1lez is an employee of Qubiotech Health Intelligence.Vincent Dor\u00e9 and Pierrick Bourgeat declare no competing interests.Alex Whittington and Roger Gunn are employees of Invicro.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}